Find information on thousands of medical conditions and prescription drugs.

Sustiva

Efavirenz (brand names Sustiva® and Stocrin®) is non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of high active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
Growth hormone
Salbutamol
Salmeterol
Sandimmune
Sandostatin
Sansert
Saquinavir
Sarafem
Satric
Scopolamine
Seasonale
Secobarbital
Secretin
Selegiline
Semprex-D
Sensipar
Sensorcaine
Serax
Serevent
Serine
Seroquel
Serostim
Serrapeptase
Sertindole
Sertraline
Serzone
Sevelamer
Sevoflurane
Sibutramine
Sildenafil
Silibinin
Simvastatin
Sinemet
Sinequan
Singulair
Sirolimus
Skelaxin
Sodium cyclamate
Solage
Soma
Somatostatin
Sotahexal
Sotalol
Sotret
Spiperone
Spiriva
Spironolactone
Sporahexal
Sporanox
SPS
SSD
Stanozolol
Stavudine
Stelazine
Stilbestrol
Stilbetin
Stimate
Stiripentol
Strattera
Streptokinase
Streptomycin
Suboxone
Subutex
Sucralfate
Sucralfate
Sufentanil
Sulbactam
Sulfamethoxazole
Sulfanilamide
Sulfasalazine
Sulforidazine
Sulla
Sulpiride
Sultamicillin
Sumatriptan
Suprefact
Suramin sodium
Sustaire
Sustiva
Suxamethonium chloride
Symmetrel
Synarel
Synercid
Synthroid
Syntocinon
Zaleplon
T
U
V
W
X
Y
Z

For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine, tenofovir or stavudine is the preferred NNRTI-based regimen.

Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV tranmission. The usual adult dose is 600 mgs once a day taken on an empty stomach at bedtime.

History

Efavirenz was approved by the Food and Drug Administration (FDA) on Sep 21, 1998, making it the fourteenth approved antiretroviral drug.

Drug interactions

  • Efavirenz is metabolized in the liver, and possesses both inhibitory and inducing effects on the 3A4 isoform of the cytochrome P450 system. This means efavirenz may interact with other drugs metabolized in the liver, requiring either increased or decreased dosages.
  • Efavirenz lowers blood levels of most protease inhibitors. Dosages of amprenavir, atazanavir, or indinavir may need to be increased. The blood levels of saquinavir are dramatically lowered, so that the two drugs cannot be used simultaneously.
  • St. John's Wort and garlic supplements may decrease efavirenz blood levels.

Side effects

  • Psychiatric symptoms, including insomnia, confusion, memory loss, and depression, are common.
  • rash nausea dizziness and headache may occur
  • efavirenz can cause birth defects
  • safety in children has not been established
  • use of efavirenz can cause a false positive in some urine tests for marijuana

Mechanism of action

Efavirenz is chemically described as (S)-6-chloro-(cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one. Its empirical formula is C14H9ClF3NO2. Efavirenz is a white to slightly pink crystalline powder with a molecular mass of 315.68. It is practically insoluble in water (<10 µg/mL).


Read more at Wikipedia.org


[List your site here Free!]



Warning on two specific 3-drug regimens: Viread + Videx + either Sustiva or Viramune
On November 12 the U.S. Food and Drug Administration's AIDS listserve noted a Dear Doctor letter from Bristol-Myers Squibb, warning that the two particular ...
EFAVIRENZ - Sustiva
The 200 mg capsules of efavirenz are gold-colored, reverse-printed with "SUSTIVA" on the body and imprinted with "200 mg" on the cap. Other dose formulations ...
Sustiva added to 48 formularies
Sustiva (efavirenz), DuPont's once-daily non-nucleoside reverse transcriptase inhibitor for the treatment of HIV infection, has been added to the Medicaid ...
FDA approves Sustiva®
DuPont Pharmaceuticals has received Food and Drug Administration approval for it new AIDS drug, Sustiva(r) (efavrienz), Sustiva(r) is the third non-nucleoside ...
Once-a-day pill falls short
People with HIV have long waited for a once-a-day pill to treat the disease, and it looked like they might finally get it this year. That was until pharmaceutical giant Gilead Sciences announced in
TMC 125: new results, large phase III trial begins
TMC125 (also spelled TMC-125, TMC 125, or etravirine), by Tibotec Pharmaceuticals Ltd., based in Cork, Ireland and now part of Johnson & Johnson, ...
Case report: parotid enlargement as a presentation of HIV infection
TO THE EDITOR: A 43-year-old man presented with a one-year history of bilateral facial swelling. Previously, he had been told the swelling was caused ...
Four antiretrovirals reduced to three after 48 weeks
A trial started over 400 antiretroviral-naive patients on an intensive 4-drug regimen--Trizivir, (AZT, 3TC, and abacavir) together with Sustiva (efavirenz).

Home Contact Resources Exchange Links ebay